非选择性β—受体阻滞剂对失代偿肝硬化患者循环及肾损伤的影响研究(5)
[14]Kamath PS，Kim WR. Advanced liver disease study group. The model for end-stage liver disease(MELD)[J].Hepatology，2007，45(3)：797-805.
[15]Child CG，Turcotte JG. Surgery and portal hypertension[J].Major Problems in Clinical Surgery，1964，1(1)：1-85.
[16]Sersté T，Francoz C，Durand F，et al. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites：A cross-over study[J].Journal of Hepatology，2011，55(4)：794-799.
[17]Robins A，Bowden A，Watson W，et al. Propranolol at modest doses does not impair survival in patients with cirrhosis and refractory ascites[J]. Hepatology，2013，71(4)：448-457.
[18]Baares R，Moitinho E，Matilla A，et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis[J]. Hepatology， 2002，36(6)：1367-1373.
[19]Reiberger T，Ulbrich G，Ferlitsch A，et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol[J].Gut， 2013， 62(11)：1634-1641.
[20]Efe C，Purnak T，Ozaslan E. The deleterious effects of propranolol on patients with cirrhosis[J]. Hepatology，2011， 53(1)：371-372.
[21]Krag A，Bendtsen F，Mller S. Does cardiac dysfunction explain deleterious effects of beta-blockers in cirrhosis and refractory ascites[J]. Hepatology，2011，53(1)：370-371.
(收稿日期：2018-02-07), 百拇医药(武瑞 刘春涛 傅晓晴)
[15]Child CG，Turcotte JG. Surgery and portal hypertension[J].Major Problems in Clinical Surgery，1964，1(1)：1-85.
[16]Sersté T，Francoz C，Durand F，et al. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites：A cross-over study[J].Journal of Hepatology，2011，55(4)：794-799.
[17]Robins A，Bowden A，Watson W，et al. Propranolol at modest doses does not impair survival in patients with cirrhosis and refractory ascites[J]. Hepatology，2013，71(4)：448-457.
[18]Baares R，Moitinho E，Matilla A，et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis[J]. Hepatology， 2002，36(6)：1367-1373.
[19]Reiberger T，Ulbrich G，Ferlitsch A，et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol[J].Gut， 2013， 62(11)：1634-1641.
[20]Efe C，Purnak T，Ozaslan E. The deleterious effects of propranolol on patients with cirrhosis[J]. Hepatology，2011， 53(1)：371-372.
[21]Krag A，Bendtsen F，Mller S. Does cardiac dysfunction explain deleterious effects of beta-blockers in cirrhosis and refractory ascites[J]. Hepatology，2011，53(1)：370-371.
(收稿日期：2018-02-07), 百拇医药(武瑞 刘春涛 傅晓晴)